Comparison of protein concentration determination of a mAb drug substance using Variable Path Length Spectroscopy and UV/VIS Spectroscopy – The regulatory dilemma: Choosing the scientifically sound analytical technique or consistency with clinical trials?

Bjorn Fehrmann
Analytical Technology | Biogen | Biogen Allé 1 | 3400 Hillerød | Denmark
e-mail: bjoern.fehrmann@biogen.com

Abstract
In recent years a new technology known as “Variable Path Length Spectroscopy” (e.g. SoloVPE from C Technologies Inc.) has been developed for the determination of protein concentration in biologics such as monoclonal antibody drug substances (mAb DS). The advantage of this new technique is its increased dynamic range and resulting minimized sample handling, which leads to increased throughput and also mitigates the risk of dilution errors compared to conventional UV. In this case study for a mAb in late-stage clinical development, it was desirable to change from a traditional UV method to SoloVPE for DS release, and it was shown that the protein concentration was significantly impacted by the choice of method (SoloVPE or SoloVPE LS (Corrected for Light Scattering)) compared to the historical conventional UV method. The decision to implement SoloVPE for DS release was considered using a risk-based approach.

Introduction
Proteins, such as monoclonal antibodies (mAb), absorb UV light at 280 nm due to the presence of aromatic amino acids, mainly tyrosine and tryptophan:

In conventional UV spectroscopy, the absorbance measured is converted to protein concentration as determined by the rearranged Beer-Lamberts law:

\[ c = \frac{A}{\epsilon \times \ell} \]

where:
- \( c \) = concentration
- \( A \) = absorbance
- \( \ell \) = path length
- \( \epsilon \) = extinction coefficient

In Variable Path Length Spectroscopy, multiple measurements at varying path lengths produce a straight line with slope \( m = \frac{A}{\ell} \). Substituting and rearranging, the concentration can be determined as follows:

\[ c = \frac{m \ell}{\epsilon} \]

Results
Results from the analytical level of the diluted samples were back-calculated to protein concentrations on the stock solution level (A, B, and C) by multiplying with the appropriate dilution factor. The pre-determined protein concentrations of A, B, and C were then set to index 100 and relative protein concentration results of each of the diluted samples were derived thus allowing evaluation of the possible impact of the difference in buffer matrices (70%, 100%, and 130%) and protein concentration results (35 mg/ml, 50 mg/ml, and 65 mg/ml); see Figure 1.

Figure 1: Variability Gauge Chart

**Discussion**
As seen in Table 1, a downward shift in protein concentration of 1.5% (p=0.0135) or 4.4% (p<0.0001) would be expected if the historical conventional UV method was to be replaced by the SoloVPE or SoloVPE LS method respectively. The difference in % seen between the means of the SoloVPE and SoloVPE LS methods show that a 2.9% (p<0.0001) overestimation of the protein concentration occurs when the result obtained at 280 nm is not corrected for light scattering. From a method performance point of view either method would be superior compared to conventional UV as the SoloVPE and SoloVPE LS methods would reduce variation to almost the same degree (% RSD: 1.2 and 1.1 respectively; UV = 3.3) (Figure 1). Hence, the scientifically sound decision would be to replace the conventional UV method with the SoloVPE LS method. However, specification limits for the protein concentration of commercial mAbs are normally in the range of target concentration ±10% or tighter. Hence, the latter option would in theory mean a critical downward shift which would significantly increase the risk of OOS results. An option to mitigate this risk would be to increase the target concentration of the mAb DS correspondingly; however this would impact all other test results accordingly (e.g. potency). Also, the adjusted protein concentration would be inconsistent with the protein concentration of the batches originally used in the clinical trials. The % difference between the means of the SoloVPE and UV method is 1.5% and thus within the RSD% of the UV method. A downward shift of this magnitude would not be critical and consistent with clinical trials would not be compromised. Originally the historical conventional UV method was maintained without correction for light scattering while pursuing a more accurate and precise methodology which now has been found. However, before SoloVPE LS is allowed to replace the historical conventional UV method, the clinical aspects and the impact on specifications/other test results should be thoroughly investigated using a risk-based approach.

**Conclusion**
- This case study concludes that the method performance of SoloVPE is superior compared to conventional UV when used to determine protein concentration in a mAb drug substance solution (50 mg/ml)
- If light scattering is evident, the regulatory aspects of replacing the UV method with SoloVPE, such as continuity and consistency, should be considered using a risk-based approach.

**Table 1: Overview of Results**

<table>
<thead>
<tr>
<th>Comparison Parameter</th>
<th>SoloVPE vs. UV</th>
<th>SoloVPE LS vs. UV</th>
<th>SoloVPE vs. SoloVPE LS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difference of Means (%)</td>
<td>1.5%</td>
<td>4.4%</td>
<td>2.9%</td>
</tr>
</tbody>
</table>

**Table 1: Overview of Results**

1. Photograph presented with permission from C Technologies Inc.